In vivo studies with the novel anticancer agent mitozolomide (NSC 353451) on Lewis lung carcinoma

Massimo Broggini, Eugenio Erba, Luciano Morasca, Carmel Horgan, Maurizio D'Incalci

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Mitozolomide is one of the most effective drugs against Lewis lung carcinoma in the mouse. Two IP doses of 40 mg/kg (days 6 and 15 after IM transplantation of 3LL) or four doses of 20 mg/kg given at various intervals (starting from day 6) increased survival time by 100%. A single IP dose of 80 mg/kg was toxic, and 10 mg/kg was ineffective even when this dose was given on eight occasions. The pharmacokinetics of mitozolomide was investigated in 3LL-bearing mice by HPLC assay. Peak drug levels were achieved in tumor 15 min after IP treatment, after which they declined according to first-order kinetics, with a half-life of 80-100 min (the same as in plasma). No dose-dependent kinetics was observed. Flow cytometry studies showed an accumulation of 3LL cells in G2M 24 h after drug treatment. This cell cycle perturbation was reversed 96 h after the inactive dose of 10 mg/kg, but not after the effective dose of 40 mg/kg.

Original languageEnglish
Pages (from-to)125-128
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume16
Issue number2
DOIs
Publication statusPublished - Mar 1986

Fingerprint

mitozolomide
Lewis Lung Carcinoma
Antineoplastic Agents
Bearings (structural)
Drug therapy
Kinetics
Pharmacokinetics
Flow cytometry
Poisons
Pharmaceutical Preparations
Tumors
Assays
Cells
Plasmas
Half-Life
Cell Cycle
Flow Cytometry
Transplantation
High Pressure Liquid Chromatography
Neoplasms

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

In vivo studies with the novel anticancer agent mitozolomide (NSC 353451) on Lewis lung carcinoma. / Broggini, Massimo; Erba, Eugenio; Morasca, Luciano; Horgan, Carmel; D'Incalci, Maurizio.

In: Cancer Chemotherapy and Pharmacology, Vol. 16, No. 2, 03.1986, p. 125-128.

Research output: Contribution to journalArticle

@article{7e625560a5674ca1b9a84d725e877a16,
title = "In vivo studies with the novel anticancer agent mitozolomide (NSC 353451) on Lewis lung carcinoma",
abstract = "Mitozolomide is one of the most effective drugs against Lewis lung carcinoma in the mouse. Two IP doses of 40 mg/kg (days 6 and 15 after IM transplantation of 3LL) or four doses of 20 mg/kg given at various intervals (starting from day 6) increased survival time by 100{\%}. A single IP dose of 80 mg/kg was toxic, and 10 mg/kg was ineffective even when this dose was given on eight occasions. The pharmacokinetics of mitozolomide was investigated in 3LL-bearing mice by HPLC assay. Peak drug levels were achieved in tumor 15 min after IP treatment, after which they declined according to first-order kinetics, with a half-life of 80-100 min (the same as in plasma). No dose-dependent kinetics was observed. Flow cytometry studies showed an accumulation of 3LL cells in G2M 24 h after drug treatment. This cell cycle perturbation was reversed 96 h after the inactive dose of 10 mg/kg, but not after the effective dose of 40 mg/kg.",
author = "Massimo Broggini and Eugenio Erba and Luciano Morasca and Carmel Horgan and Maurizio D'Incalci",
year = "1986",
month = "3",
doi = "10.1007/BF00256161",
language = "English",
volume = "16",
pages = "125--128",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - In vivo studies with the novel anticancer agent mitozolomide (NSC 353451) on Lewis lung carcinoma

AU - Broggini, Massimo

AU - Erba, Eugenio

AU - Morasca, Luciano

AU - Horgan, Carmel

AU - D'Incalci, Maurizio

PY - 1986/3

Y1 - 1986/3

N2 - Mitozolomide is one of the most effective drugs against Lewis lung carcinoma in the mouse. Two IP doses of 40 mg/kg (days 6 and 15 after IM transplantation of 3LL) or four doses of 20 mg/kg given at various intervals (starting from day 6) increased survival time by 100%. A single IP dose of 80 mg/kg was toxic, and 10 mg/kg was ineffective even when this dose was given on eight occasions. The pharmacokinetics of mitozolomide was investigated in 3LL-bearing mice by HPLC assay. Peak drug levels were achieved in tumor 15 min after IP treatment, after which they declined according to first-order kinetics, with a half-life of 80-100 min (the same as in plasma). No dose-dependent kinetics was observed. Flow cytometry studies showed an accumulation of 3LL cells in G2M 24 h after drug treatment. This cell cycle perturbation was reversed 96 h after the inactive dose of 10 mg/kg, but not after the effective dose of 40 mg/kg.

AB - Mitozolomide is one of the most effective drugs against Lewis lung carcinoma in the mouse. Two IP doses of 40 mg/kg (days 6 and 15 after IM transplantation of 3LL) or four doses of 20 mg/kg given at various intervals (starting from day 6) increased survival time by 100%. A single IP dose of 80 mg/kg was toxic, and 10 mg/kg was ineffective even when this dose was given on eight occasions. The pharmacokinetics of mitozolomide was investigated in 3LL-bearing mice by HPLC assay. Peak drug levels were achieved in tumor 15 min after IP treatment, after which they declined according to first-order kinetics, with a half-life of 80-100 min (the same as in plasma). No dose-dependent kinetics was observed. Flow cytometry studies showed an accumulation of 3LL cells in G2M 24 h after drug treatment. This cell cycle perturbation was reversed 96 h after the inactive dose of 10 mg/kg, but not after the effective dose of 40 mg/kg.

UR - http://www.scopus.com/inward/record.url?scp=0022634046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022634046&partnerID=8YFLogxK

U2 - 10.1007/BF00256161

DO - 10.1007/BF00256161

M3 - Article

C2 - 3948297

AN - SCOPUS:0022634046

VL - 16

SP - 125

EP - 128

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -